Global burden of liver disease: 2023 update
Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
S Urban, C Neumann-Haefelin, P Lampertico - Gut, 2021 - gut.bmj.com
Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with
hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable …
hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable …
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a …
H Wedemeyer, K Schöneweis, P Bogomolov… - The Lancet Infectious …, 2023 - thelancet.com
Background Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV)
and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing …
and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing …
[HTML][HTML] Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma
Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer …
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer …
The changing context of hepatitis D
The global epidemiology of hepatitis D is changing with the widespread implementation of
vaccination against hepatitis B. In high-income countries that achieved optimal control of …
vaccination against hepatitis B. In high-income countries that achieved optimal control of …
EASL Clinical Practice Guidelines on hepatitis delta virus
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B virus to complete its
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies
Background & Aims Chronic hepatitis D (CHD) is the most severe form of chronic viral
hepatitis but its role in the development of hepatocellular carcinoma (HCC) remains …
hepatitis but its role in the development of hepatocellular carcinoma (HCC) remains …
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
M Jachs, C Schwarz, M Panzer, T Binter… - Alimentary …, 2022 - Wiley Online Library
Summary Background and Aim Bulevirtide (BLV) blocks the uptake of the hepatitis D virus
(HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally …
(HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally …